Abstract:G protein-gated inwardly rectifying K+ (GIRK) channels are critical mediators of excitability in the heart and brain. Enhanced GIRK-channel activity has been implicated in the pathogenesis of supraventricular arrhythmias, including atrial fibrillation. The lack of selective pharmacological tools has impeded efforts to investigate the therapeutic potential of cardiac GIRK-channel interventions in arrhythmias. Here, we characterize a recently identified GIRK-channel inhibitor, VU0468554. Using whole-cell electrophysiological approaches and primary cultures of sinoatrial nodal cells and hippocampal neurons, we show that VU0468554 more effectively inhibits the cardiac GIRK channel than the neuronal GIRK channel. Concentration-response experiments suggest that VU0468554 inhibits Gβγ-activated GIRK channels in noncompetitive and potentially uncompetitive fashion. In contrast, VU0468554 competitively inhibits GIRK-channel activation by ML297, a GIRK-channel activator containing the same chemical scaffold as VU0468554. In the isolated heart model, VU0468554 partially reversed carbachol-induced bradycardia in hearts from wild-type mice but not Girk4-/- mice. Collectively, these data suggest that VU0468554 represents a promising new pharmacological tool for targeting cardiac GIRK channels with therapeutic implications for relevant cardiac arrhythmias. SIGNIFICANCE STATEMENT: Although cardiac GIRK-channel inhibition shows promise for the treatment of supraventricular arrhythmias, the absence of subtype-selective channel inhibitors has hindered exploration into this therapeutic strategy. This study utilizes whole-cell patch-clamp electrophysiology to characterize the new GIRK-channel inhibitor VU0468554 in human embryonic kidney 293T cells and primary cultures. We report that VU0468554 exhibits a favorable pharmacodynamic profile for cardiac over neuronal GIRK channels and partially reverses GIRK-mediated bradycardia in the isolated mouse heart model.

Comparison of the Effects of Dc031050, A Class Iii Antiarrhythmic Agent, on Herg Channel and Three Neuronal Potassium Channels

Electrophysiologic Study of the Biphasic Effects of Cyclovirobuxine D on Arrhythmias

Automated Tight Seal Electrophysiology for Assessing the Potential Herg Liability of Pharmaceutical Compounds

Electrophysiological Properties of Hbi-3000: A New Antiarrhythmic Agent with Multiple-Channel Blocking Properties in Human Ventricular Myocytes

Characterization of hERG K+ channel inhibition by the new class III antiarrhythmic drug cavutilide

Comparative Effects of Liensinine and Neferine on the Human Ether-a-go-go-related Gene Potassium Channel and Pharmacological Activity Analysis

Mechanisms Underlying the Antiarrhythmic Action of Compound ALM-802

The ion channel basis of pharmacological effects of amiodarone on myocardial electrophysiological properties, a comprehensive review

Electrophysiological Effects of Cyclovirobuxine D on the Ventricular Papillary Muscle of Rats

Comparative study of carvedilol and quinidine for inhibiting hKv4.3 channel stably expressed in HEK 293 cells.

Inhibitory effect of aloperine on transient outward potassium currents in rat cardiac myocytes

Comparison of the Electrophysiological Effects of S49, CSH087 and CSH068 in Rat Ventricular Cells.

Electrophysiological characterization of a small molecule activator on human ether-a-go-go-related gene (hERG) potassium channel.

Characterization of VU0468554, a New Selective Inhibitor of Cardiac G Protein-Gated Inwardly Rectifying K+ Channels

Antagonism of 4-Substituted 1,4-Dihydropyridine-3,5-dicarboxylates Toward Voltage-Dependent L-type Ca2+ Channels Ca V 1.3 and Ca V 1.2.

Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing.

Electrophysiologic Effects of SB-237376: a New Antiarrhythmic Compound with Dual Potassium and Calcium Channel Blocking Action.

Recording ten-fold larger IKr conductances with automated patch clamping using equimolar Cs+ solutions

Effects of quinidine on hERG potassium current and hERG channel protein in HEK293 cell line

Characterization of amiodarone action on currents in hERG-T618 gain-of-function mutations

Inhibitory Actions of the Phosphatidylinositol 3-Kinase Inhibitor LY294002 on the Human Kv1.5 Channel.